These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 8729590)
1. Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial. Foley DP; Serruys PW Br J Clin Pract Suppl; 1996 Jan; 77A():40-53. PubMed ID: 8729590 [TBL] [Abstract][Full Text] [Related]
2. Fluvastatin for the prevention of restenosis after coronary balloon angioplasty: angiographic and methodological background of the fluvastatin angioplasty restenosis trial. Foley DP; Serruys PW Br J Clin Pract Suppl; 1994 Dec; (77):39-50. PubMed ID: 19496272 [TBL] [Abstract][Full Text] [Related]
3. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group. Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025 [TBL] [Abstract][Full Text] [Related]
4. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Serruys PW; Foley DP; Jackson G; Bonnier H; Macaya C; Vrolix M; Branzi A; Shepherd J; Suryapranata H; de Feyter PJ; Melkert R; van Es GA; Pfister PJ Eur Heart J; 1999 Jan; 20(1):58-69. PubMed ID: 10075142 [TBL] [Abstract][Full Text] [Related]
5. The influence of plasma lipoprotein (a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty. Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial. Lloyd GW; Jackson G; Foley DP; Boersma E; Shepherd J; Serruys PW Atherosclerosis; 2001 Oct; 158(2):445-54. PubMed ID: 11583725 [TBL] [Abstract][Full Text] [Related]
6. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy. Arampatzis CA; Goedhart D; Serruys PW; Saia F; Lemos PA; de Feyter P; Am Heart J; 2005 Feb; 149(2):329-35. PubMed ID: 15846273 [TBL] [Abstract][Full Text] [Related]
7. Relation of lumen size to restenosis after percutaneous transluminal coronary balloon angioplasty. Lovastatin Restenosis Trial Group. Waksman R; Kosinski AS; Klein L; Boccuzzi SJ; King SB; Ghazzal ZM; Weintraub WS Am J Cardiol; 1996 Jul; 78(2):221-4. PubMed ID: 8712148 [TBL] [Abstract][Full Text] [Related]
8. Fluvastatin reduces the 4-year cardiac risk in patients with multivessel disease. Lemos PA; de Feyter PJ; Serruys PW; Saia F; Arampatzis CA; Disco C; Mercado N; Mainar V; Morís C; van den Bos AA; Berghoefer G Int J Cardiol; 2005 Feb; 98(3):479-86. PubMed ID: 15708183 [TBL] [Abstract][Full Text] [Related]
9. Effects of statins on restenosis after coronary stent implantation. Kamishirado H; Inoue T; Sakuma M; Tsuda T; Hayashi T; Takayanagi K; Node K Angiology; 2007; 58(1):55-60. PubMed ID: 17351158 [TBL] [Abstract][Full Text] [Related]
10. Experimental and early clinical experience with reviparin-sodium for prevention of restenosis after percutaneous transluminal coronary angioplasty. Preisack MB; Karsch KR Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S55-8; discussion S59-60. PubMed ID: 8180331 [TBL] [Abstract][Full Text] [Related]
11. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). Lemos PA; Serruys PW; de Feyter P; Mercado NF; Goedhart D; Saia F; Arampatzis CA; Soares PR; Ciccone M; Arquati M; Cortellaro M; Rutsch W; Legrand V Am J Cardiol; 2005 Feb; 95(4):445-51. PubMed ID: 15695126 [TBL] [Abstract][Full Text] [Related]
12. Fluvastatin: a review of its use in lipid disorders. Langtry HD; Markham A Drugs; 1999 Apr; 57(4):583-606. PubMed ID: 10235694 [TBL] [Abstract][Full Text] [Related]
13. [Preventive mechanisms and effects of pemirolast potassium on restenosis after percutaneous transluminal coronary angioplasty: serial coronary angiography and intravascular ultrasound studies]. Yoshinuma M J Cardiol; 1999 Feb; 33(2):81-8. PubMed ID: 10087476 [TBL] [Abstract][Full Text] [Related]
14. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Levy RI; Troendle AJ; Fattu JM Circulation; 1993 Apr; 87(4 Suppl):III45-53. PubMed ID: 8462180 [TBL] [Abstract][Full Text] [Related]
15. [Percutaneous transluminal coronary angioplasty for restenosis following Palmaz-Schatz stenting: larger size balloons are more effective?]. Kishi K; Hiasa Y; Suzuki N; Miyamoto H; Takahashi T; Hosokawa S; Tanimoto M; Otani R J Cardiol; 1999 Aug; 34(2):55-60. PubMed ID: 10466086 [TBL] [Abstract][Full Text] [Related]
16. Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) Study. Jørgensen B; Thaulow E; Am Heart J; 2003 Jun; 145(6):1030-5. PubMed ID: 12796759 [TBL] [Abstract][Full Text] [Related]